All Oncology News

LY4170156 was well tolerated and generated promising efficacy data in patients with recurrent, platinum- resistant high-grade serous ovarian cancer.

Patients with relapsed/refractory MCL had poor treatment outcomes with BTK inhibition, which decreased in quality as the line of therapy advanced.

The addition of mFOLFOX6 and bevacizumab to atezolizumab improved PFS compared with atezolizumab monotherapy in dMMR/MSI-H mCRC.

Encorafenib plus cetuximab and FOLFIRI significantly improved response vs standard therapy in first-line BRAF V600E–mutant metastatic colorectal cancer.

Penipulimab plus anlotinib and chemotherapy showed improved efficacy compared with chemotherapy alone in treatment-naïve metastatic pancreatic cancer.

Nivolumab plus ipilimumab continued to yield an efficacy and safety benefit vs lenvatinib or sorafenib in previously untreated, unresectable HCC.

An international group of thoracic oncology specialists reviewed key updates in first-line NSCLC from the 2025 ESMO Asia Congress.

MedEduChat, an EHR-integrated AI agent provided individualized prostate cancer education for patients according to researchers at Mayo Clinic.

The FDA will increase its flexibility on CMC requirements for cell and gene therapies to speed their development and better support BLA planning.

A BLA for ivonescimab plus chemotherapy in EGFR-mutant NSCLC following treatment with a third-generation EGFR TKI has been submitted to the FDA.

Brian Slomovitz, MD, discusses key trials and surgical advances for patients with ovarian cancer.

FDA announces new CRL for tabelecleucel in EBV+ Post-Transplant Lymphoproliferative Disease.

Experts in the field of CLL/SLL discussed the role of BTK inhibitors and degraders in R/R CLL/SLL during an OncLive Scientific Interchange and Workshop.

Atezolizumab plus bevacizumab could yield superior outcomes compared with TACE in intermediate-stage HCC.

The top 5 OncLive TV videos of the week cover insights in lung cancer, bladder cancer, gastrointestinal cancer, and multiple myeloma.

A rusfertide NDA for polycythemia vera has been submitted to the FDA, a tafasitamab combination boosts PFS over R-CHOP in DLBCL, and more.

Results from ReFocus showed a manageable safety profile and positive antitumor activity for lirafugratinib in FGFR2-mutated cholangiocarcinoma.

Neoadjuvant tislelizumab plus chemoradiotherapy yielded improved response rates in gastric cancer and gastroesophageal junction adenocarcinoma.

Adjuvant pembrolizumab did not improve RFS vs placebo in HCC following complete radiological response after surgical resection or local ablation.

Zolbetuximab plus chemotherapy delivered maximal clinical benefits when AEs were managed effectively in CLDN18.2-positive advanced gastric/GEJ cancer.

CAR-like T-cells, PD-1 inhibitor, and SOX was active in previously untreated metastatic gastric or GEJ adenocarcinoma.

ECOG performance status captured only part of the patient experience in advanced gastric or gastroesophageal junction adenocarcinoma.

Enolen, a localized enzalutamide–eluting implant, has received FDA fast track designation for low- to intermediate-risk, localized prostate cancer.

Pumitamig/nab-paclitaxel produced responses in advanced TNBC in a phase 2 study, informing its further evaluation in the phase 3 ROSETTA Breast-01 trial.

Orca-T improved clinical outcomes both overall and across patient subgroups with varied demographic and clinical features in the Precision-T trial.

Bone marrow Immune Atlas in myeloma linked immune system/tumor interactions with disease aggressiveness, potentially improving prognosis and risk stratification.

Total neoadjuvant chemotherapy plus chemoradiotherapy was identified as a preferred candidate for future study in resectable gastric adenocarcinoma.

Zolbetuximab plus mFOLFOX6 and nivolumab was effective and tolerable across biomarker-defined subgroups in unresectable gastric/GEJ adenocarcinoma.

HERIZON-GEA-01 is the first phase 3 study to demonstrate a median PFS greater than 1 year, and a median OS greater than 2 years in metastatic GEA.